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design and followed rosacea patients enrolled in North Carolina
Medicaid and who were prescribed at least one study medication
(topical metronidazole, adapalene, azelaic acid, permethrin, and
sulfacetamide). Patients’ demographic characteristics, number of
metronidazole reﬁlls, and different components of health care
costs were examined. Multivariate regression analyses were used
to examine factors associated with prescription reﬁlls and health
care costs. RESULTS: Out of the total 2587 rosacea patients,
the majority (~69%, n = 1771) had 1 or more prescriptions for
topical metronidazole. Most of the patients in this study were
Whites (73%). After controlling for other variables, increasing
age was associated with higher number of metronidazole reﬁlls
and health care costs (both p < 0.001). As compared to Whites,
African American patients had signiﬁcantly lower number of
metronidazole reﬁlls (p < 0.001). As compared to Whites,
African American and other races were associated with an 8.6%
and 10.3% decrease in total health care costs respectively (both
p < 0.001). An increase in number of metronidazole reﬁlls was
not associated with an increase in health care costs. CONCLU-
SIONS: Patients’ race was signiﬁcantly associated with the
number of topical metronidazole reﬁlls. Patients’ health care
costs increased with increasing age and charges paid for prescrip-
tions. Topical metronidazole seems to be an economically fea-
sible treatment option for Medicaid-enrolled patients with
rosacea.
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OBJECTIVES: To assess the use of biologicals for psoriasis
according to NICE technology appraisal 103 and assess actual
treatment practice within the NHS. METHODS: To date 13 UK
sites have enrolled into the chart review. Site selection was based
upon recruiting three centres with prescribers of biologicals
across nine geographical locations. Information was collected
for patients initiated on a biological between August 2006 and
December 2007 for plaque psoriasis. Patients were excluded if
they had a diagnosis of psoriatic arthritis. The data was collated
on demographics, co-morbidities, treatment courses, Psoriasis
Area Severity Index (PASI) and Dermatology Life Quality Index
(DLQI), and reasons for stopping treatment. Data was analysed
to ascertain adherence to NICE, and to explore regimens used in
practice and discontinuation rates. RESULTS: Recruitment is
being completed. This information will be reported as a full
dataset in the poster. Thus far data has been collected for 66
patients across 7 centres. The average age of patients reported
was 46 years. Eight-one percent of patients were initiated on
etanercept 25 mg twice weekly, 3% on etanercept 50 mg twice
weekly, and 8% on efalizumab. Of those patients who initiated
etanercept 25 mg twice weekly, the average length of the ﬁrst
course of treatment was 169 days (approximately 24 weeks).
Patients discontinued etanercept treatment for various reasons
including adverse events and lack of efﬁcacy. Fourteen switched
to efalizumab following ﬁrst etanercept course. Many patients
did not have PASI and DLQI recorded 12 weeks post treatment
commencement. CONCLUSIONS: Many of the NICE criteria
for prescribing biologicals have been followed; however there are
some areas which require focus including recording of PASI and
DLQI scores within three months. The review also showed that
the intermittent dosage assumed by NICE in the appraisal of
these drugs may not be realistic and modiﬁcation is needed in
further technology appraisals.
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OBJECTIVES: Evaluation of quality of care of leg ulcers in the
area of Hamburg, assessment of treatment with respect to
guidelines, recording of patients’ quality of life and burden of
treatment in the area of this community. METHODS: Potential
criteria for the evaluation of quality of care were derived from
the German AWMF-guideline and relevant international guid-
ance. Wound experts (physicians and nurses) derived 20 prior-
ity criteria and indicators which deﬁne “optimal treatment” in
a national Delphi consensus. A total score for quality of care
was developed, ranging from 0–100 (no to perfect quality of
care). Then, a representative sample of n = 520 patients with
chronic leg ulcers of any origin was consecutively drawn.
Patients were approached in wound clinics, ofﬁce-based prac-
tices, nursing homes, home care services and special centres for
homeless and drug addicts, thus including a large spectrum of
220 health care providers. All patients were interviewed, all
wounds photographed and examined by trained wound
experts. Patients were asked to ﬁll a questionnaire addressing
quality of life, prior therapy and health services/care.
RESULTS: Data of 502 patients were analysed, including leg
ulcers with venous (63%), mixed (23%), vasculitic (2%) and
other (12%) pathogenesis. A high proportion of patients
(78.6%) were treated with modern wound dressings. Pain and
compression therapy was mainly in accordance with guidelines.
However, deﬁcits were detected for diagnostics (e.g. angiology,
biopsies, pain measurement) and concomitant wound treat-
ments. A high proportion of patients still had a markedly
impaired quality of life. The mean total score for quality of
care was below 60. CONCLUSIONS: In spite of mostly “lege
artis” topical treatment, many patients in North Germany are
not treated in accordance to relevant guidelines. The quality of
care scoring method developed was shown to be a sensitive tool
for health services research and evaluation.
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OBJECTIVES: To compare the evolution of prostaglandin ana-
logue (PGA) and beta-blocker (BB) prescriptions in ﬁve European
countries in the context of the health care regulation environ-
ment. METHODS: Data from different sources were gathered: 1)
1998–2003 prescriptions delivered by the central pharmacy of
the Padova geographical area; 2) IMS data (1995–2006) from
France, Germany, Italy, Spain and the United-Kingdom; and 3)
an extraction of glaucoma-treated patients from the UK-GPRD.
Drugs were grouped in 3 classes: PGA, BB and others. Yearly
market shares were calculated. Treatment persistence survival
curves were estimated from the Italian and UK data and the three
drug groups were compared using the Cochran Mantel Haenszel
test. RESULTS: According to the Padova data, BB market share
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